Clinical Features of 24 Patients With Rebound-Associated Vertebral Fractures After Denosumab Discontinuation: Systematic Review and Additional Cases

Severe rebound-associated vertebral fractures after denosumab discontinuation: nine clinical cases report

(2016) Olivier Lamy et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Cancel the denosumab holiday

(2016) M. R. McClung   OSTEOPOROSIS INTERNATIONAL

Hypercalcemia after discontinuation of long-term denosumab treatment

(2016) A. S. Koldkjær Sølling et al.   OSTEOPOROSIS INTERNATIONAL

Denosumab and teriparatide transitions in postmenopausal osteoporosis (the DATA-Switch study): extension of a randomised controlled trial

(2015) Benjamin Z Leder et al.   LANCET

Severe spontaneous vertebral fractures after denosumab discontinuation: three case reports

(2015) B. Aubry-Rozier et al.   OSTEOPOROSIS INTERNATIONAL

Multiple clinical vertebral fractures following denosumab discontinuation

(2015) A. D. Anastasilakis et al.   OSTEOPOROSIS INTERNATIONAL

Rebound-associated vertebral fractures after discontinuation of denosumab—from clinic and biomechanics

(2015) A. W. Popp et al.   OSTEOPOROSIS INTERNATIONAL

Discontinuation of denosumab and associated fracture incidence: Analysis from the Fracture Reduction Evaluation of Denosumab in Osteoporosis Every 6 Months (FREEDOM) Trial

(2012) Jacques P Brown et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Effects of Denosumab Treatment and Discontinuation on Bone Mineral Density and Bone Turnover Markers in Postmenopausal Women with Low Bone Mass

(2011) Henry G. Bone et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Clinical complications following thyroid fine-needle biopsy: a systematic review

(2009) Stergios A. Polyzos et al.   CLINICAL ENDOCRINOLOGY

Denosumab for Prevention of Fractures in Postmenopausal Women with Osteoporosis

(2009) Steven R. Cummings et al.   NEW ENGLAND JOURNAL OF MEDICINE

Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: A randomized blinded phase 2 clinical trial

(2008) Paul D. Miller et al.   BONE